易瑞生物(300942) - 2025 Q1 - 季度财报

Revenue and Profitability - The company's revenue for Q1 2025 was ¥49,342,908.97, representing a 35.28% increase compared to ¥36,475,073.45 in the same period last year[5] - Net profit for the current period was -¥4,233,747.89, an improvement from -¥7,273,762.66 in the previous period, indicating a reduction in losses[19] - Basic and diluted earnings per share improved to -¥0.0083, a 53.11% increase from -¥0.0177 in the previous year[5] - Basic and diluted earnings per share improved to -¥0.0083 from -¥0.0177 in the previous period[20] Cash Flow - The net cash flow from operating activities was negative at ¥1,415,234.47, a decline of 115.04% compared to a positive cash flow of ¥9,412,805.78 in the same period last year[5] - The company reported a net cash inflow from operating activities of ¥67,267,138.19, compared to ¥65,457,841.42 in the previous period[22] - The net cash flow from investing activities was positive at 160,720,396.32, a substantial improvement from a negative cash flow of -35,652,211.67 in the prior period, reflecting successful investment recovery efforts[23] - The net cash flow from financing activities was positive at 656,140.77, down from 46,120,022.70 in the previous period, suggesting a decrease in financing activities[23] - The cash outflow from operating activities totaled 68,682,372.66, compared to 56,045,035.64 in the previous period, showing an increase in operational cash expenses[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,443,075,606.54, a decrease of 0.97% from ¥1,457,165,935.92 at the end of the previous year[5] - The company's total current assets amount to 730,932,473.54 RMB, a decrease from 751,616,151.89 RMB at the beginning of the period[15] - The total liabilities decreased slightly to ¥576,727,249.39 from ¥586,923,364.94, a decline of 1.7%[16] - The total liabilities include accounts payable of 51,219,299.39 RMB, down from 58,762,442.61 RMB[15] - The company reported a decrease in contract liabilities to 19,356,363.94 RMB from 24,992,820.15 RMB[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,731[11] - The largest shareholder, Yirui (Hainan) Venture Capital Co., Ltd., holds 33.86% of shares, totaling 135,901,179 shares, with 80,000,000 shares pledged[11] - The second-largest shareholder, Zhu Hai, owns 16.87% of shares, amounting to 67,692,519 shares, with 16,850,000 shares pledged[11] Operating Costs and Expenses - The operating costs surged by 153.85% to ¥23,502,052.28, primarily due to increased revenue and a higher proportion of equipment-related products[9] - Total operating costs increased to ¥55,561,251.36, up 25.2% from ¥44,390,455.72 in the previous period[18] - Research and development expenses decreased to ¥8,238,945.94 from ¥10,280,504.62, reflecting a 19.8% reduction[19] - The cash paid to employees increased to 27,403,778.22 from 26,272,515.25, indicating a rise in payroll expenses[23] Investment Performance - The company recorded a 912.75% increase in fair value changes, amounting to ¥903,784.58, attributed to the fair value changes of financial products[9] - The company’s investment income received cash increased by 842.57% to ¥1,762,483.79, reflecting higher returns from financial investments[9] - The company recorded a net investment loss of -¥2,089,627.24, worsening from -¥1,663,633.85 in the previous period[19] - The cash inflow from investment activities totaled 219,005,301.56, significantly higher than 30,357,118.70 in the previous period, indicating strong investment performance[23] Tax and Other Income - The company experienced a 100% decrease in cash received from tax refunds, dropping to ¥0.00 from ¥7,225,626.82, due to reduced export tax refunds[9] - The cash paid for taxes increased to 1,248,847.70 from 681,690.26, reflecting higher tax obligations[23] - Other comprehensive income after tax was -¥209,889.51, compared to -¥66,277.39 in the previous period, indicating a larger loss in this category[20] Cash and Cash Equivalents - The company reported a significant increase in cash and cash equivalents, rising by 42.89% to ¥419,229,213.25 due to the redemption of financial products[9] - Cash and cash equivalents increased to 419,229,213.25 RMB from 293,399,311.14 RMB, reflecting a growth of approximately 42.9%[14] - The total cash and cash equivalents at the end of the period amounted to 418,886,074.71, a decrease from 500,350,687.09 at the end of the previous period[23] - The impact of exchange rate changes on cash and cash equivalents was positive at 1,792,812.67, contrasting with a negative impact of -1,278,804.52 in the previous period[23]